| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Annals of Surgical Oncology, Vol 7, Issue 8 568-574, Copyright © 2000 by Society of Surgical Oncology
ARTICLES |
L. A. Newman, W. C. Wood, R. V. Sellin, M. Morrow, C. Vogel and S. E. Singletary
Department of Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston 77030, USA.
The prevalence of breast cancer (a hormonally driven neoplasm) in the United States, the potential health benefits of estrogen replacement therapy for postmenopausal women, and the burgeoning research focusing on selective estrogen receptor modulators (SERMs) have resulted in additional complexity in managing breast cancer. In an attempt to clarify existing data, the Society of Surgical Oncology sponsored a symposium entitled "Estrogens and Antiestrogens in Managing the Patient with Breast Cancer" at its 52nd Annual Cancer Symposium. This conference was held in March 1999 and was chaired by Dr. S. Eva Singletary, Professor of Surgery and Chief of the Surgical Breast Section at The University of Texas M. D. Anderson Cancer Center in Houston, Texas. The following is a review of the material presented by the symposium participants.
This article has been cited by other articles:
![]() |
P. Greenwald Clinical Trials in Cancer Prevention: Current Results and Perspectives for the Future J. Nutr., December 1, 2004; 134(12): 3507S - 3512S. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |